anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Nelfinavir
Trial phase: Phase 2 | Phase 3
ATC code: J05AE04
SMILES: [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSc1ccccc1)NC(=O)c1cccc(O)c1C)[C@H](C(=O)NC(C)(C)C)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, underdosing).
Eligibility criteria:
Inclusion Criteria:

HIV infected- confirmed by ELISA or 2 prior viral loads >2000
18 years or older
Under consideration to initiate or change their HAART regimens (based on current consensus treatment guidelines) as directed by their primary care physicians.
Measurable HIV Neurocognitive Impairment (HNCI)
Willing and able to undergo at least 3 lumbar punctures safely during the course of the study.
Potential subjects must have a Karnofsky score of > or = to 60 within 60 days prior to study entry.
Potential subjects must have a CD4 cell count obtained within 60 days prior to study entry.

Exclusion Criteria:

Presence of serious illness, including HIV-related opportunistic infections, requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 14 days prior to study entry.
Presence of neurologic disorders other than HIV judged to be the principal cause of neurocognitive impairment.
Presence of active, severe psychiatric disorders (e.g., major depression, schizophrenia) that would interfere with interpretation of the study evaluations or adherence to the study protocol or that might make their participation in the study problematic or unsafe.
Presence of active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
Use of any immunomodulator (interferons, interleukins, cyclosporine), vaccine, or investigational therapy including dexamethasone within 30 days prior to study entry.
Inability to provide informed consent.
Enrollment in other ARV treatment studies, unless the study is: 1) observational; 2) a compassionate use study that predated the current study; 3) one that does not require specific interventions (or one that does not dictate the regimen); or 4) one that does not include NP testing.
A positive serum or urine pregnancy test, if female and of reproductive potential.
Intervention: Nelfinavir
Trial phase: Phase 2 | Phase 3
ATC code: J05AE04
SMILES: [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSc1ccccc1)NC(=O)c1cccc(O)c1C)[C@H](C(=O)NC(C)(C)C)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen designed to suppress plasma Viral Load, but not to expected to have targeted CNS penetration.
Eligibility criteria:
Inclusion Criteria:

HIV infected- confirmed by ELISA or 2 prior viral loads >2000
18 years or older
Under consideration to initiate or change their HAART regimens (based on current consensus treatment guidelines) as directed by their primary care physicians.
Measurable HIV Neurocognitive Impairment (HNCI)
Willing and able to undergo at least 3 lumbar punctures safely during the course of the study.
Potential subjects must have a Karnofsky score of > or = to 60 within 60 days prior to study entry.
Potential subjects must have a CD4 cell count obtained within 60 days prior to study entry.

Exclusion Criteria:

Presence of serious illness, including HIV-related opportunistic infections, requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 14 days prior to study entry.
Presence of neurologic disorders other than HIV judged to be the principal cause of neurocognitive impairment.
Presence of active, severe psychiatric disorders (e.g., major depression, schizophrenia) that would interfere with interpretation of the study evaluations or adherence to the study protocol or that might make their participation in the study problematic or unsafe.
Presence of active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
Use of any immunomodulator (interferons, interleukins, cyclosporine), vaccine, or investigational therapy including dexamethasone within 30 days prior to study entry.
Inability to provide informed consent.
Enrollment in other ARV treatment studies, unless the study is: 1) observational; 2) a compassionate use study that predated the current study; 3) one that does not require specific interventions (or one that does not dictate the regimen); or 4) one that does not include NP testing.
A positive serum or urine pregnancy test, if female and of reproductive potential.
Intervention: Cycloserine
Trial phase: Not Applicable
ATC code: J04AB01
SMILES: N[C@@H]1CONC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: D-Cycloserine: CBT including prolonged exposure enhanced by virtual reality D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
Eligibility criteria:
Inclusion Criteria:

English-speaking adults
Between the ages of 18 and 70
Exposed to the WTC Attacks (were in towers or in the immediate area) or veterans of the Iraq War
Diagnosed with PTSD symptoms.

Exclusion Criteria:

Presence of current organic mental disorder
Schizophrenia
Bipolar disorder
Depression with psychotic features
Current substance dependence
Delusional disorder
Active suicidal ideation, intent, or plan
Active homicidal ideation, intent, or plan
Use of pacemaker
Medically unstable
Pregnant or lactating
A history of severe renal disease
History of seizures
Currently taking anticoagulants, ethionamide (Trecator-SC) or isoniazid (INH)
History of allergic reaction to cycloserine.
Intervention: Cycloserine
Trial phase: Not Applicable
ATC code: J04AB01
SMILES: N[C@@H]1CONC1=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: 50 mg cycloserine
Eligibility criteria:
Inclusion Criteria:

female and male smokers, aged 18 to 55 years;
history of smoking daily for the past 12 months, at least 10 cigarettes daily;
CO level > 10ppm;
for women: not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods other than OCP;
Non-treatment seeking nicotine dependent smokers.

Exclusion Criteria:

history of heart disease, renal or hepatic diseases or other medical conditions that the physician investigator deems as contraindicated for the patient to be in the study;
regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and/or recent psychiatric diagnosis and treatment for Axis I disorders including major depression, bipolar affective disorder, schizophrenia and panic disorder within the past year;
current dependence on alcohol or on drugs other than nicotine;
regular use of any other tobacco products than cigarettes, including smokeless tobacco and nicotine products;
allergy to cycloserine;
subjects with epilepsy or a history of seizures;
Treatment seeking nicotine dependent smokers.
Intervention: INSULIN DETEMIR
Trial phase: Phase 4
ATC code: A10AE05
SMILES: CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 121
Group description: Aggressive FPG (fasting plasma glucose) titration target range group
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes
1-3 oral treatments
Insulin naive
BMI (Body Mass Index) less than or equal to 45

Exclusion Criteria:

Pregnancy
Retinopathy
Cardiac disease
Uncontrolled hypertension
Recurrent hypoglycaemia
Intervention: INSULIN DETEMIR
Trial phase: Phase 4
ATC code: A10AE05
SMILES: CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 122
Group description: Conventional FPG (fasting plasma glucose) titration target range group
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes
1-3 oral treatments
Insulin naive
BMI (Body Mass Index) less than or equal to 45

Exclusion Criteria:

Pregnancy
Retinopathy
Cardiac disease
Uncontrolled hypertension
Recurrent hypoglycaemia
Intervention: Relistor
Trial phase: Phase 2
ATC code: A06AH01
SMILES: C[N+]1(CC2CC2)CCC23c4c5ccc(O)c4OC2C(=O)CCC3(O)C1C5.[Br-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Participants received MNTX 12 mg SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant was enrolled.
Eligibility criteria:
Inclusion Criteria:

Male and female participants greater than or equal to (>=) 18 years of age.
Participants must have undergone an orthopedic procedure (that is, total knee or hip replacement, spinal fusion, or reduction of fracture(s) with or without surgical fixation post trauma).
Participants must be receiving opioid analgesics (a mu agonist only-not to include agents with mixed mechanisms of action such as tramadol or buprenorphine) after the procedures and be expected to require daily opioid analgesics for at least 7 days post randomization.
Participants must be acutely constipated following their orthopedic procedure.
Participants must receive all doses of study drug in either hospitals or rehabilitation facilities.
Participants must sign an informed consent form.
Females of childbearing potential must have a negative pregnancy test and use appropriate birth control throughout the study.
Body weight within range of 40 kilograms (kg) - 150 kg (88 - 330 pounds [lbs]).

Exclusion Criteria:

Participants with known hypersensitivity to methylnaltrexone, naltrexone, or naloxone.
Participants who received any investigational new drug (experimental) in the previous 30 days.
Participants who have received a laxative (for example, lactulose) or an enema within 48 hours prior to the first dose.
Participants with constipation not attributed to post procedure opioids.
Participants with a history of alcohol or prescription or non-prescription drug abuse within the past 2 years.
Female participants who are pregnant or lactating.
Participants with a known history of chronic active hepatitis B or hepatitis C virus or human immunodeficiency virus (HIV) infection.
Intervention: Dexmedetomidine
Trial phase: Not Applicable
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 65
Group description: sedative

dexmedetomidine : Sedative
Eligibility criteria:
Inclusion Criteria:

Healthy, human volunteers, age 19-65.
American Society of Anesthesiology (ASA) class I-II for inclusion criteria

Exclusion Criteria:

Pregnancy
Respiratory disease (severe asthma, emphysema)
Cardiac disease (coronary artery disease, congestive heart failure)
Symptomatic reflux disease
Advanced rheumatic disease involving cervical spine
Propofol or egg allergy
Neurological disease (stroke, intracranial processes)
Severe anemia
Intervention: Dexmedetomidine
Trial phase: Phase 4
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 1
Group description: Dexmedetomidine 2 micrograms/kilogram (mcg/kg) intranasal
Eligibility criteria:
Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for participation:

The subject is 6 months to 6 years of age
The subject's American Society of Anesthesiologists (ASA) physical status is ASA 1 or 2 (see appendix 1)
The subject is scheduled for elective bilateral myringotomy with tube placement

The subject's parent/legally authorized guardian has given written informed consent to participate

Exclusion Criteria:

Subjects will be excluded from study participation if any of the following exclusion criteria exists:

The subject has a history or a family (parent or sibling) history of malignant hyperthermia
The subject has known significant renal or hepatic disorders determined by medical history, physical examination or laboratory tests
The subject has a known or suspected allergy to opioid analgesics or dexmedetomidine
The subject has history of. cardiovascular issues which would preclude the use of dexmedetomidine, (e.g. Down's Syndrome, dysrhythmias, conditions where hypotension is to be avoided)
The subject has know central nervous system disease or neurological impairment
The subject is an ASA classification of 3 or greater (See Appendix 1)
The subject has a medical condition requiring an intravenous induction (i.e. severe uncontrolled gastro-esophageal reflux)
The subject refuses inhalation induction
The subject is scheduled for a surgical sub-procedure (i.e. adenoidectomy, tonsillectomy)
Intervention: Andrographolide
Trial phase: Phase 2
SMILES: [H][C@]12CCC(=C)[C@@H](C/C=C3/C(=O)OC[C@H]3O)[C@]1(C)CC[C@@H](O)[C@@]2(C)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 51
Group description: Subjects who fulfilled all entry criteria and randomized HMPL-004 arm will receive HMPL-004 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
Eligibility criteria:
Inclusion Criteria:

Have active confirmed Crohn's Disease (confirmed radiographically, endoscopic, or histologically), with a CDAI of 220-400 at baseline screen

Exclusion Criteria:

They have received anti-TNF-α antibody within 3 months of starting study medication, or cyclosporine, tacrolimus, thalidomide or mycophenolate mofetil within 2 months of starting study medication
Intervention: INSULIN DETEMIR
Trial phase: Not Applicable
ATC code: A10AE05
SMILES: CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 10
Group description: These people receive insulin detemir first, then insulin glargine. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.
Eligibility criteria:
Inclusion Criteria:

Type 1 diabetes
Treated with long-acting and meal time insulin therapy for at least 2 years
Ages 18 to 60 years of age
Glycosylated hemoglobin value between 7 - 9 mg/dL
C-peptide value less than 1.0 pmol/ml 90 minutes after oral Boost Plus administration.

Exclusion Criteria:

Advanced complications of diabetes (nephropathy, retinopathy, significant neuropathy, coronary artery disease)
Severe medical illness or medical conditions including congestive heart failure, angina, liver failure or renal failure
Pregnancy
Alcohol or drug abuse or dependence within three months of study entry
Less than 50 % agreement on 50-item Food Questionnaire with the Food Array "buffet style" study meal.
Women of child-bearing age not adhering to the following contraceptive methods: oral contraceptives, barrier methods including condoms or diaphragm, or abstinence.
Intervention: Misoprostol
Trial phase: Phase 3
ATC code: A02BB01 | G02AD06 | M01AE56
SMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 77
Group description: Women in Group 1 will be administered two tablets (2 100 mcg misoprostol tablets), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
Eligibility criteria:
Inclusion Criteria:

Women presents with spontaneous fetal death
Gestational age of fetus between 14-28 weeks

Exclusion Criteria:

Transmural uterine scar;
Allergies or other contraindications to use of misoprostol;
Placental abruption with active hemorrhage;
Complete placenta previa;
Extreme uterine structural anomalies;
Or other contraindications to vaginal delivery of the fetus;
Presentation in active labor (moderate to severe contractions every 10 minutes); or
Four or more previous deliveries
Intervention: Misoprostol
Trial phase: Phase 3
ATC code: A02BB01 | G02AD06 | M01AE56
SMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 76
Group description: Women in Group 1 will be administered two tablets (a 100 mcg misoprostol tablet and a placebo tablet made to resemble a 100 mcg misoprostol tablet), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
Eligibility criteria:
Inclusion Criteria:

Women presents with spontaneous fetal death
Gestational age of fetus between 14-28 weeks

Exclusion Criteria:

Transmural uterine scar;
Allergies or other contraindications to use of misoprostol;
Placental abruption with active hemorrhage;
Complete placenta previa;
Extreme uterine structural anomalies;
Or other contraindications to vaginal delivery of the fetus;
Presentation in active labor (moderate to severe contractions every 10 minutes); or
Four or more previous deliveries
Intervention: Cycloserine
Trial phase: Phase 4
ATC code: J04AB01
SMILES: N[C@@H]1CONC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 111
Group description: D-Cycloserine

D-Cycloserine: 50 mg/oral one hour prior to extinction task
Eligibility criteria:
Inclusion Criteria:

Veterans and civilians with an age range of 18 to 65 years
Participants must be physically healthy volunteers

Exclusion Criteria:

Individuals who fall outside the age range
Individuals with medical conditions that would interfere with participation
Other criteria
Intervention: Thiamine
Trial phase: Phase 2
ATC code: A11DA01
SMILES: Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 131
Group description: Receives thiamine
Eligibility criteria:
Inclusion Criteria:

History of heart failure on a loop diuretic.
Worsening dyspnea over the past 24 hours.
Currently dyspneic sitting or supine, on or off oxygen.
Radiographic cephalization of vessels. This criteria is not needed if the patient has no other reason for being dyspneic after being evaluated in the emergency department.
Elevated NT pro-BNP (>450).
Able to communicate in English or Spanish.
Able and willing to provide informed consent.
Age > 18 years.
A primary admitting diagnosis of acute decompensated heart failure.

Exclusion Criteria:

Renal failure on dialysis.
Severe valvular disease.
EKG criteria for acute myocardial infarction (ST segment elevation > 1mm on two contiguous leads).
Initial troponin elevated.
Ventricular arrhythmia (ventricular tachycardia or fibrillation).
Supraventricular arrhythmia (atrial fibrillation / flutter) with a ventricular rate >120 beats per minute.
Taking a daily thiamine supplementation (any multivitamin or specific thiamine supplementation within the past 2 weeks. Fortified foods, such as cereals, are acceptable
Taking a daily fatty acid supplement.
Pregnancy as determined by standard serum or urine b-HCG assay.
Intervention: Glycerin
Trial phase: Not Applicable
ATC code: A06AG04 | A06AX01
SMILES: OCC(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 16
Group description: One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
Eligibility criteria:
Inclusion Criteria:

Age > 18 years
symptoms of dry eye
no other history of ophthalmic problems

Exclusion Criteria:

Use of any ocular lubricant or ointment in the past 36 hours
use of contact lenses or excessive eye lid cosmetics on the study day